System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

José L Casado is an expert in Infectiology at Hospital Universitario Ramón y Cajal (Spain). As of June 2026, ScienceLeadR ranks José L Casado in the top 1% of experts worldwide for HIV Infections. José L Casado has authored 320 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 1 of them ongoing. SLR score: 921 (community average: 125). How the SLR is computed.

LeadR Profile

José L Casado Hospital Universitario Ramón y Cajal Spain
921 ScienceLeadR Reputation 921

Unlock

Register Login
Network Map

Infectiology

Subspecialties: Immunology - Pharmacy - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Hospital Universitario Ramón y Cajal

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 320

Citations

Citations: 8 580 1st author: 79 Last author: 32 Unique author: 2

Main journals

AIDS 27
HIV Med 21
Enferm Infecc Microbiol Clin 17
Clin Infect Dis 14
J Antimicrob Chemother 14

Best Journals

N Engl J Med 2
Ann Oncol 1
Lancet Infect Dis 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Neuropsychiatric Tolerability of Long-Acting Cabotegravir and Rilpivirine in People With HIV With Prior INSTI-Related CNS Toxicity: A Real-World Cohort Study.
PMID 41978826 — incidence, cohort studies, hiv, rilpivirine, integrase inhibitors, therapeutics, history		Open Forum Infect Dis20260
Long-Term Serologic Outcomes Following Treatment of Syphilis in People With HIV: A Prospective Cohort Study.
PMID 41846571 — cd4 lymphocyte count, syphilis, cohort studies, hiv, therapeutics, communicable diseases		Clin Infect Dis20260
Towards tuberculosis elimination in people with HIV on antiretroviral therapy: evidence from a two-decade nationwide cohort in Spain.
PMID 41792852 — incidence, hiv, tuberculosis, risk factors, therapeutics		Infect Dis Poverty20260
Urinary Exosome-Derived microRNAs as Biomarkers of Tenofovir Disoproxil Fumarate (TDF)-Induced Renal Toxicity in People with HIV-1.
PMID 41176188 — hiv-1, tenofovir, micrornas, biomarkers, exosomes, fumarates, hiv		Int J Antimicrob Agents20250
From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV.
PMID 41041971 — tenofovir, genes, mdr, pharmaceutical preparations, probability, drug therapy, maintenance, cholesterol, hiv, emtricitabine, therapeutics		J Antimicrob Chemother20250

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 5
Phase 4 2
Phase 1 1
Phase 2 1
Phase 2/Phase 3 1
Phase 3 1

By status:

Completed 9
Recruiting 2

By type:

Interventional 6
Observational 5

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 2
multicentric5to9 0
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 40

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Differences in Immune Response Among HIV 1 infected Individuals With Previous or Current COVID 19 (CoVIHDis)
NCT04526977 — cytokines, toll-like receptors, cells, hiv-1, sars-cov-2, immunoglobulins, hiv, covid-19, immunity, severe acute respiratory syndrome-related coronavirus, t-lymphocytes, infections, plasma		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS